Navamedic Asa · OSL:NAVA
Navamedic Asa — Q2 2021 Earnings Presentation
21 slides from Navamedic Asa's earnings presentation, August 2021
Slide 1: First half and second quarter results 2021
1H/Q2 2021 First half and second quarter results 2021 Navamedic ASA Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Q2 2021 highlights
Q2 2021 highlights Strong underlying portfolio performance and exciting new product additions Operations and sales In 1H 2021, revenues grew by 27.5% compared to the same period last year Strong growth for Mysimba®, Alflorex® and ThermaCare® Launched Cysticina® REVENUE GROSS MARGIN EBITDA Entered in
Slide 3: Navamedic in brief
Navamedic in brief Nordic pharma company targeting growth in Northern Europe A reliable supplier of high- Presence in all Nordic ~ 30 professionals with Ambitious growth strategy, quality consumer health, countries, Baltics and strong local competence in high-potential pipeline and medical nutrition
Slide 4: Ambition of building a leading Nordic pharma company
Navamedic in brief Ambition of building a leading Nordic pharma company targeting growth in Northern Europe OUR TARGET 1 2 3 20% annual growth STRENGTHEN THE SECURE AND GROWTH THROUGH from 2021 with a mid- CORE INCREASE THE M&A to long-term ambition VALUE THROUGH of building a 500 MNOK company with
Slide 5: Key portfolio developments
Key portfolio developments Continued growth for key products in H1 2021, and Mysimba®, ThermaCare® and Alflorex® in particular MEDICAL CONSUMER BRANDED SPECIALTY NUTRITION HEALTH GENERICS PHARMA Medical nutrition products for Gastro, pain, urology, other Antibiotics, cardiology, generics Obesity, ur
Slide 6: Medical nutrition – Positive development across markets
Medical nutrition – Positive development across markets GROWTH DRIVERS Q2 2021 REVENUE • Launched three new products 13.3 MNOK in the quarter: Glycosade Lemon, K. Flo and K. Yo (Q2 2020: 11.1 MNOK) • Upgoing trend for key products IEM Products for treatment of Inborn Errors of Metabolism (IEM), a li
Slide 7: Consumer Health - launch of new and unique products
Consumer Health - launch of new and unique products GROWTH DRIVERS Q2 2021 REVENUE • ThermaCare® developed as planned 8.3 MNOK • Strong performance of Alforex® (Q2 2020: 4.2 MNOK) • Cysticina® launched 7
Slide 8: Branded Generics – Stable development and new products introduced
Branded Generics – Stable development and new products introduced GROWTH DRIVERS Q1 2021 REVENUE • Won the tender for certain antibiotics to the 17.9 MNOK Norwegian market in the quarter (Q2 2020: 14.6 MNOK) • Volatility for Imdur® due to out-of-stock situation 8
Slide 9: Specialty pharma – very strong growth
Specialty pharma – very strong growth GROWTH DRIVERS Q2 2021 REVENUE • Strong performance of 26.5 MNOK Mysimba® both in Norway and Sweden (Q2 2020: 12.1MNOK) • Successful rollout of Patient Support Program 9
Slide 10: Financials
FINANCIALS @ Navamedic
Slide 11: Key consolidated profit and loss figures
Financials In Q2 2021, revenues grew by 56.7% Key consolidated profit and loss figures compared to Q2 last year and 27.5% in H1 vs last year (in NOK '1000) Q2 2021 Q2 2020 YTD 2021 YTD 2020 Year 2020 Continued strong Gross Profit of Operating revenues 66 014 42 135 124 659 97 776 209 877 39.3% due t
Slide 12: Assets
Financials Change in Goodwill is due to Assets minor currency effects (in NOK '1000) 30.06.2021 30.06.2020 31.12.2020 Increase in Other intangible Goodwill 62 602 64 288 64 472 assets is due to the Deferred tax assets 9 168 9 242 9 168 acquisition/booking of the Other intangible assets 29 983 8 704
Slide 13: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 30.06.2021 30.06.2020 31.12.2020 Equity ratio of 51.5% Total equity 148 894 131 527 129 486 Non-current license liabilities 8 385 8 383 3 343 Non-current liabilities to financial institutions 20 120 20 796 20 870 Increase in Equity is mainly due Non-c
Slide 14: Cash flow Group – total operations
Financials Cash flow Group – total operations The cash flow from Operating Activities is due to Net profit (in NOK '1000) Q2 2021 Q2 2020 YTD 2021 YTD 2020 Year 2020 coupled with changes in Net Net cash flow from operating activities -4 322 -6 305 -16 756 -21 620 -3 180 Working Capital Net cash flow
Slide 15: Summary & Outlook
SUMMARY & OUTLOOK @ Navamedic
Slide 16: Summary and outlook
Navamedic ASA Summary and outlook Building a leading Nordic pharma company targeting growth in Northern Europe In Q2 2021, we have • Strengthened the core by driving underlying growth in the existing portfolio • Entered into distribution agreement for PrecisionBiotics Zenflore® • Secured tender for
Slide 17: Q&A
Q&A @ Navamedic
Slide 18: Thank you for your attention!
Thank you for your attention! Navamedic’s Q3 2021 presentation will be on 4 November 2021
Slide 19: Appendix
APPENDIX @ Navamedic
Slide 20: Basis for preparation and definitions of Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 21: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any